AstraZeneca AB - search results

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

imfinzi

astrazeneca ab - durvalumab - carcinom, non-small cell lung - antineoplastiska medel - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

qtrilmet

astrazeneca ab - metformin hydroklorid, saxagliptin, dapagliflozin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - qtrilmet är indicerat hos vuxna i åldern 18 år och äldre med typ 2-diabetes mellitus:för att förbättra glykemisk kontroll när metformin med eller utan sulphonylurea (su) och antingen saxagliptin eller dapagliflozin inte ger tillräcklig glykemisk kontroll. när du redan behandlas med metformin och saxagliptin och dapagliflozin.

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

gardette 160 mikrogram/4,5 mikrogram/inhalation inhalationsspray, suspension

astrazeneca ab - budesonid; formoterolfumaratdihydrat - inhalationsspray, suspension - 160 mikrogram/4,5 mikrogram/inhalation - budesonid 160 mikrog aktiv substans; formoterolfumaratdihydrat 4,5 mikrog aktiv substans

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)

symbicort 80 mikrogram/2,25 mikrogram/puff inhalationsspray, suspension

astrazeneca ab - budesonid; formoterolfumaratdihydrat - inhalationsspray, suspension - 80 mikrogram/2,25 mikrogram/puff - formoterolfumaratdihydrat 2,25 mikrog aktiv substans; budesonid 80 mikrog aktiv substans

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

beyfortus

astrazeneca ab - nirsevimab - immunförsvaret sera och immunglobuliner, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Thụy Điển - Tiếng Thụy Điển - Läkemedelsverket (Medical Products Agency)